EGFR and non-small cell lung carcinoma: Approved tyrosine kinase inhibitors such as gefitinib, erlotinib and lapatinib (V–VII, Figure 2) for the treatment of non-small cell lung cancer have led to tremendous development of novel EGFR inhibitors in the last decade [30].